GSK (GSK LN) Q4 (GBP): Revenue 8.62bln (exp. 8.42bln), Adj. EPS 0.255 (exp. 0.224), affirms FY26 guidance and 2031 sales outlook

GSK's Q4 earnings surpassed expectations on both revenue and adjusted EPS, suggesting robust demand, particularly in vaccine sales and Shingrix.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Additional European Equity News

Newsquawk Daily European Equity Opening News - 4th February 2026

GSK (GSK LN) Q4 (GBP): Revenue 8.62bln (exp. 8.42bln), Adj. EPS 0.255 (exp. 0.224), affirms FY26 guidance and 2031 sales outlook

Indian Trade Minister says the US trade deal will offer a competitive advantage to Indian exporters and our priority is to energy energy security for our citizens

Panasonic (6752 JT) 9M (JPY): Net profit 125bln (prev. 288bln Y/Y), Net revenue 5.88tln (prev. 6.40tln Y/Y), raises FY26 net profit 240bln (prev. 157.3bln) and revenue 7.70tln (prev. 818.8bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Vaccine sales 2.29bln (exp. 2.20bln)
  • Shingrix revenue 1.01bln (exp. 827mln)

FY26 guidance:

  • Expect 2026 turnover growth of between 3-5%; Core operating profit growth of between 7-9%; Core EPS growth of between 7-9%
Context

By affirming their FY26 guidance, the company indicates confidence in continuing growth, which could positively influence sentiment in the pharmaceuticals sector and bolster the stock's performance in the near term.

Related headlines

The whole workspace, free to try.

Try it free